- Glucagon-Like Peptide-1 Agonist Receiver (LPG-1) Drugs are a class of medications used to manage type 2 diabetes and treat obesity.
- WHILE MANY DRUGS IN THIS CLASS ARE RELATIVELE NEW, REFIDLY LEARNING THAT THE DRUG’S BENEFITS MAY EXTEND WELL BEYOND MANAGING Average BLOOD SUGAR SUGAR LEVENLS AND AIDING IN WEIGHT LOSS.
- Recently Researchers Driving Review to Examine What Effects LP-1 Medications May Have On Cognitive Functioning and Mental Health Issues.
- The Scientists Found Mixed Results: While Sub Sudies Showed The Drugs Offer Neuroprotective Benefits, Other Studies in The Review Raised the Alarm That Sub Sub Sub Sub Sub Sub Subs In The Drug Class May Increased Depression and Suicide Ideality.
GLUCAGON-Like Peptide-1 Receiver Agonists (LPG-1RAS OR LPG-1) Medications have Skyrocketed into popularity over the past few years. Pharmaceutical Companies Initially Relay The Drugs Ozempic (Semaglutide) and Mounjaro (Tirzepatide) to Help with Blood Sugar Control in Type 2 Diabetes.
Since the medication also contribute to weight loss, Both Drugs were latease Release as Wegovy and Zepbound to Help People with Obesity. While Semaglutide and Tirzepatide Are The Most Popular of the LPG-1 Drugs at The Moment, Sub Othher Medications in This Class Include Liraglutide and Dreamaglutide.
WHILE MANY PEOPLE WHHO Take LP-1 Medications for Weight Loss Experience Tremendous Benefits From The Drugs, The Drugs May have other uses. For Example, A Recent Study Showed That GLP-1S May Help Curbe Drinking.
In a review driver by scientists from the United Kingdom and Canada, Refracchers Examined Numberus Studies to Determine How these Drugs Affect Cognitive Abilities and Mental Health. WHILE SUB STUDIES THE REVIEWED WERE POSITIVE REGUGDING IMPROVING COGNITIVE FUNCTIONING, OTHERS HAD MIXED Results.
The Study Appears in
GLP-1 COUL HELP REDUCE BRAIN INFLAMMATION
According to the
LPG-1 Drugs Also Improve Blood Flow to the Heart and Act Directly on The Hypothalamus to increase the sensation of being full after meal. KisidesSe Metabolic Effects, LPG-1 Drugs Also Appear to have an impact on brain Health and mental Health.
Since Sub Sudi Show That Glp-1 Drugs May have an impact on addictive behaviors, This Makes Scientists Wonder What Neurological Impacts The Drug Can Have.
The Refers Who Driving The New Review used data from Hundreds of Clinical Studies, preclinical studies, Controlled Trials, and Meta-Analys to Learn More About How Glp-1 Medications Impact The Brain.
Submit the Scientists Focused on Included Animal Studies on Alzheimer’s and Parkinson’s Desecases, Dementia Risk in People With A Background of Obesity Or Type 2 Diabetes, and Cognitive Functioning Tests in People With Obesity Or Diabetes.
The Refectchers Also Looked at Studies Thatzed Howlp-1 Drugs AFFECTED SUBSTANCE ABUSE Disorders, Psychotic Disorders, and Mood and Anxiety Disorders.
LPG-1 Drugs Are Promising in Submit Areas and Need More Research in Others. For Instance, The Review Showed that GLP-1 Drugs May Have Promising Outcomes For People With Dementia or Oter Neurological Disorders.
“There Is Also Evidence for Mechanisms Involve A Reduction of Neuroinflammation, an Increase in Synaptic Functioning, as Well as The Restorration of Brain Pathways of Insulin Signaling That May Lead To Improved Memory Formation and Therefore a Positive Effect In Alzheimer’s Disease And Parkinson ‘ Disease, ”Note The Authors.
More than 100 preclinical Research Studies suggests that GLP-1 Drugs Could Protect Against Cognitive Decline. Acese Findings are significant to People with Alzheimer’s and Parkinson’s.
The Refectchers Note That GLP-1 Drugs Offer Protection by Reducting Harmful Brain Proteins, Inflammation, and Insulin Resistance.
What is the Effect of LPG-1 Drugs on Mental Health?
At The Same Time, The Findings for Clinical Studies were More Mixed, and Long-Trials Showed The Possibility of A Lower Dementia Risk with Thes Drugs, But SHORTER Trials Did Not Show Cognitive Improvements.
The Review Findings for Howlp-1s AFFECT Substance Abuse Disorders Were Largely Promising, But the Authors Note That Human Studies Are Mostly in the Early Stages.
The Studies Using Animal Research Showed that GLP-1 Drugs Helped reduces cravings for severe substances by APFFECTING Dopamine Pathways. Sub of the substances tested include alcohol, Nicotine, Cocaine, and opioids.
The Refectchers Were Also Interested in How LP-1 Drugs Can Protect Mental Health. The Number of Studies Available in Humans Was Limited, and the results were Mixed.
The Refectchers Notted That the Use of LPG-1 Drugs in People with Schizophrenia Spectrum Conditions Helped with Comorbid Diabetes and Obesity. The Researchers Found This Promising in Terms of Mitigating Sub of the Cardiometabolic Issues Sesues that antipsychotic Drugs May Create.
The Research Showed That GLP-1S Can Offer Neuroprotive Benefits in People Taking Mood Stabilizers. However, Submithing the Researchers Came Across in Their Review was People with Anxiety and Depression Subtimes Experience Wordened Symptoms.
Submit reports notted Concerns over Exenatide and Semaglutide Worsening Depressive Symptoms, and a Larger Study suggested to Slightly Increased Risk of Suicidal Behavior With Liraglutide.
“Overall, AS LPG-1ras Become Increasingly prescribed, Further Pharmacovigilance Studies Are Warrad,” Note The Authors.
Experts printed with inflammation reduction of glp-1s
Mir Ali, MD, A Board-Certified General Surgeon, Bariatric Safe and Medical Director of Memorialcare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, Spoke With Medical News Today about the review.
“LPG-1 agonists appeal to have Applications Beyond Diabetes and Weight Loss; However, it is not easy to separate before benefits from Improvement in Diabetes or Weight Loss, ”Ali commented. “In Other Words, It is difficult to provide that methods provides direct benefit, rather than to secondary benefit from Eithher Weight Loss or Control of Diabetes.”
He Said More Research is Needed to Determine If and How LP-1 Drugs Can Cause Mood Disturbances.
“Changes in Mood Can Oscur From Many Sources, Including Weight Loss, SO Further Research is necessary to delineate The Current Mechanism,” Poleded Out Ali. “Overall, Serious Side Effects, Such as Suicidal Ideations are Vray Rare.”
“I find the reduction in inflammation must come. Chronic inflammation can lead to host of medical problems, so any reduction in inflammation can beneficial. ”
– Mir Ali, MD
David Merrill, MD, A Board-Certified Geriatric Psychiatrist at Providence Saint John’s Health Center in Santa Monica, CA, and Singleton Endowed Chair in Integrative Brain Health, Also Spoke With MNT.
“This Study Adds to a Growing Body of Evidence Suggesting That GLP-1 Agonist Receiver-Originally Medications Designed for Diabetes and Obesity-May has neuroprotective neuroprotective Effective Broader Effective,” Said Merrill.
“The Findings are Intruguing Because they align with what we’ve see in preclinical models and under human studies: GLP-1RAS Appear to reduce neuroinflammation, Improve insulin signaling in the brain, and potentially slow Process Associated With Cognitive Decline,” “Hey.”
While Merrill Sees potential for the future of LPG-1 Drugs to Be Helpful outside Treating Type 2 Diabetes and Obesity, He Also Understands The Need For More Studies.
“While The Data Is Promising, It’s Still Early. We Need Well-deasigned, Long-Term Clinical Trials To Determine Whether these drarugs can be effffively used to preserve cognitive function or Even Even neurodegenerative treative conditions like Alzheimer’s Disease, ”Merrill Emphasized.
